Poseida Therapeutics, Inc. (PSTX)
NASDAQ: PSTX · IEX Real-Time Price · USD
3.060
-0.170 (-5.26%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Poseida Therapeutics Revenue
Poseida Therapeutics had revenue of $82.50M in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $28.14M with 172.09% year-over-year growth. In the year 2023, Poseida Therapeutics had annual revenue of $64.70M.
Revenue (ttm)
$82.50M
Revenue Growth
-40.82%
P/S Ratio
3.60
Revenue / Employee
$250,006
Employees
330
Market Cap
296.69M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 64.70M | -65.79M | -50.42% |
Dec 31, 2022 | 130.49M | 99.25M | 317.73% |
Dec 31, 2021 | 31.24M | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AngioDynamics | 324.01M |
Tactile Systems Technology | 276.67M |
Alimera Sciences | 90.22M |
Enanta Pharmaceuticals | 72.88M |
SOPHiA GENETICS | 64.18M |
Aquestive Therapeutics | 51.50M |
Adaptimmune Therapeutics | 18.36M |
Verrica Pharmaceuticals | 8.91M |
PSTX News
- 20 days ago - Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum - PRNewsWire
- 6 weeks ago - Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders - PRNewsWire
- 2 months ago - Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024 - PRNewsWire
- 2 months ago - Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting - PRNewsWire
- 2 months ago - Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology - PRNewsWire
- 3 months ago - Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting - PRNewsWire
- 3 months ago - Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus - PRNewsWire
- 3 months ago - Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma - PRNewsWire